UNION has built a differentiated clinical-stage pipeline with multiple clinical programs in immunology and infectious diseases based on three distinct product candidates from two differentiated compound classes that are represented by our lead molecules orismilast and niclosamide.

*) Innovent Biologics has exclusive rights to oral orismilast and an option on topical orismilast for China, HK, Taiwan and Macau; UNION retains remaining worldwide rights.

**) Platform study sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, and funded by LifeArc, Addenbrookes Charitable Trust, Kidney Research UK and UNION.

***) Worldwide rights out-licensed to Ceva.

Expanded access policy to be found here